Phase III studies of investigational gantenerumab did not meet their primary endpoints of slowing clinical decline in early Alzheimer’s disease, the Roche Group said. Beta-amyloid removal also was lower than expected with the drug.
Source: Advances in technologies to detect early signs of disease from a blood sample are helping doctors to identify the memory-robbing disorder more accurately and to screen participants more quickly for trials of potential treatments.
GCG Global Healthcare are specialists in healthcare excellence. Driven by a desire to improve healthcare and clinical solutions for everyone – patients, medical professionals and facilities. Gloreen G at GCG has vast experience and understanding of the specialist medical and diagnostic imaging market. This gives GCG the ability to ensure that you receive the very best salary and incentives package, including leave entitlements, days off, paid conferences and radiology expenses.
Subscribe to our newsletter
LET US PROVIDE YOU WITH THE LATEST MEDICAL NEWS, NETWORKING AND PROFESSIONAL
DEVELOPMENT OPPORTUNITIES, AND EXCITING JOB OPENINGS FOR RADIOLOGISTS.